The THO complex as a key mRNP biogenesis factor in development and cell differentiation

The THO complex is a key component in the co-transcriptional formation of messenger ribonucleoparticles that are competent to be exported from the nucleus, yet its precise function is unknown. A recent study in BMC Biology on the role of the THOC5 subunit in cell physiology and mouse development provides new clues to the role of the THO complex in cell differentiation

An evaluation of pixel-based methods for the detection of floating objects on the sea surface

Ship-based automatic detection of small floating objects on an agitated sea surface remains a hard problem. Our main concern is the detection of floating mines, which proved a real threat to shipping in confined waterways during the first Gulf War, but applications include salvaging, search-and-rescue operation, perimeter, or harbour defense. Detection in infrared (IR) is challenging because a rough sea is seen as a dynamic background of moving objects with size order, shape, and temperature similar to those of the floating mine. In this paper we have applied a selection of background subtraction algorithms to the problem, and we show that the recent algorithms such as ViBe and behaviour subtraction, which take into account spatial and temporal correlations within the dynamic scene, significantly outperformthe more conventional parametric techniques, with only little prior assumptions about the physical properties of the scene

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen

New methods for handling the range dependence of the clutter spectrum in non-sidelooking monostatic STAP radars

peer reviewedWe address the problem of detecting slow-moving targets using a non-sideloking monostatic space-time adaptive processing (STAP) radar. The construction of optimum weights at each range implies the estimation of the clutter covariance matrix. This is typically done by straight averaging of neighboring data snapshots. The range-dependence of these snapshots generally results in poor performance. We present two new methods that handle the rangedependence by exploiting the geometry of the direction-Doppler curves

New Solutions to the Problem of Range Dependence in Bistatic STAP Radars

peer reviewedWe address the problem of detecting slow-moving targets using a space-time adaptive processing (STAP) radar. The construction of optimum weights at each range implies the estimation of the clutter covariance matrix. This is typically done by straight averaging of neighboring data snapshots. However, in bistatic configurations, these snapshots are rangedependent. As a result, straight averaging results in poor performance. After reviewing existing methods for handling the range-dependence, we present new methods exploiting the precise shape of the bistatic direction-Doppler curves